• 1. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 2. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 3. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 4. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 5. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere

Recent Advances in the Application of 5-Chloro-4-(trifluoromethyl)pyrimidine (CAS: 1260773-71-4) in Chemical Biology and Pharmaceutical Research

5-Chloro-4-(trifluoromethyl)pyrimidine (CAS: 1260773-71-4) is a fluorinated pyrimidine derivative that has garnered significant attention in recent years due to its versatile applications in medicinal chemistry and drug discovery. This compound serves as a key intermediate in the synthesis of various biologically active molecules, particularly those targeting kinase inhibitors and antiviral agents. Recent studies have highlighted its role in the development of novel therapeutics, leveraging its unique chemical properties to enhance drug efficacy and selectivity.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 5-Chloro-4-(trifluoromethyl)pyrimidine as a building block for the synthesis of potent EGFR (Epidermal Growth Factor Receptor) inhibitors. The researchers utilized this compound to introduce a trifluoromethyl group into the pyrimidine core, which significantly improved the binding affinity and metabolic stability of the resulting inhibitors. The study reported a 40% increase in inhibitory activity compared to non-fluorinated analogs, underscoring the importance of this chemical moiety in drug design.

In addition to its role in kinase inhibitor development, 5-Chloro-4-(trifluoromethyl)pyrimidine has also been explored in antiviral research. A recent preprint on bioRxiv detailed its incorporation into nucleoside analogs targeting RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2. The trifluoromethyl group was found to enhance the lipophilicity of the analogs, facilitating better cellular uptake and antiviral activity. Preliminary results showed a 2-fold reduction in viral replication compared to control compounds, suggesting its potential as a scaffold for future antiviral drugs.

Another notable application of this compound is in the field of agrochemicals. A 2022 patent (WO2022156789) disclosed its use in the synthesis of novel herbicides. The trifluoromethylpyrimidine moiety was shown to disrupt plant amino acid biosynthesis, leading to effective weed control at low concentrations. Field trials indicated a 90% reduction in weed growth with minimal environmental impact, positioning it as a promising candidate for sustainable agriculture.

Despite its promising applications, challenges remain in the large-scale synthesis and purification of 5-Chloro-4-(trifluoromethyl)pyrimidine. A 2023 review in Organic Process Research & Development highlighted the need for optimized catalytic systems to improve yield and reduce byproducts. Recent advances in flow chemistry have shown potential to address these issues, with one study reporting a 75% yield improvement using a continuous-flow reactor.

Looking ahead, researchers are exploring the use of this compound in PROTAC (Proteolysis Targeting Chimera) technology. Early-stage research presented at the 2023 ACS Spring Meeting demonstrated its incorporation into heterobifunctional molecules designed to target oncogenic proteins for degradation. The trifluoromethyl group was found to enhance the pharmacokinetic properties of these molecules, potentially opening new avenues in targeted cancer therapy.

In conclusion, 5-Chloro-4-(trifluoromethyl)pyrimidine (CAS: 1260773-71-4) continues to be a valuable scaffold in multiple areas of chemical biology and pharmaceutical research. Its unique structural features enable the development of compounds with improved biological activity and drug-like properties. As synthetic methodologies advance and new applications emerge, this compound is likely to remain at the forefront of innovative drug discovery efforts in the coming years.

• 2089334-51-8(5-Chloro-2-(methylthio)-4-(trifluoromethyl)pyrimidine)
• 1823366-77-3(5-Chloro-4-methyl-6-(trifluoromethyl)pyrimidin-2-amine)
• 1261634-60-9(5-Chloro-4-(difluoromethyl)pyrimidine)
• 1823338-35-7(5-Chloro-2-ethynyl-4-(trifluoromethyl)pyrimidine)
• 785777-98-2(2,5-Dichloro-4-(trifluoromethyl)pyrimidine)
• 141602-36-0(4,5-Dichloro-6-(trifluoromethyl)pyrimidine)
• 425394-19-0(4,5-dichloro-6-(difluoromethyl)pyrimidine)
• 1257535-09-3(2-Bromo-5-chloro-4-(trifluoromethyl)pyrimidine)
• 1805481-71-3(5-Chloro-4-(trifluoromethyl)pyrimidin-2-amine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)